» Articles » PMID: 642401

Anti-HBc, HBeAg and DNApolymerase Activity in Healthy HBsAg Carriers and Patients with Inflammatory Liver Diseases

Overview
Journal Klin Wochenschr
Specialty General Medicine
Date 1978 Mar 15
PMID 642401
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In this paper we report on anti-HBc-titers, HBcAg, DNApolymerase activity in the serum and intracellular HBsAg in healthy HBsAg-carriers and patients with HBsAg-positive inflammatory liver diseases. 32/44 patients with acure virus-B-hepatitis were negative for anti-HBc in the first week of the disease. Anti-HBc-titers in healthy HBsAg-carriers varied between 1:10 and 1:32,000 (medium titer 1:4,000). In HBsAg-positive CAH we found a medium titer between 1:32,000 and 1:64,000, in cases with CPH of about 1:16,000. All autoimmune type CAH showed anti-HBc-titers less than 1:10. By immunofluorescence we could demonstrate in a group of 71 asymptomatic HBsAg-carriers in none of the healthy HBsAg-carriers HBcAg in the liver cell nuclei. In contrast HBcAg could only be found in 4/5 HBsAg positive CAH- and 6/9 CPH patients. No elevated DNApolymerase activity could be demonstrated in healthy HBsAg-carriers. Out of 44 patients with virus-B-hepatitis only 3 showed elevated DNApolymerase activity. On the other hand DNApolymerase elevation was demonstrable in 17/37 cases with CAH and 9/15 with CPH. The investigations showed a strong correlation between the demonstration of HBcAg in the serum and the DNApolymerase activity. The characteristic findings enabled us to differentiate between "healthy" HBsAg-carriers and HBsAg-carriers with inflammatory liver diseases.

Citing Articles

Comparison of indicators for dane particles.

Hess G, Arnold W, Meyer zum Buschenfelde K Klin Wochenschr. 1980; 58(7):371-6.

PMID: 7392542 DOI: 10.1007/BF01477280.


Quantitation of HBeAG and anti-HBe by RIA in sera of chronic HBsAG carriers and individuals with type B hepatitis.

Arnold W, Hess G, Kawakami H, Meyer zum Buschenfelde K Klin Wochenschr. 1981; 59(12):679-83.

PMID: 7253542 DOI: 10.1007/BF02593860.


IgM antibody to hepatitis B core antigen (anti-HBc IgM) in "healthy" HBsAg carriers: a longitudinal study of 75 cases.

Dromeyer H, Arnold W, Kryger P, Nielsen J, Meyer zum Buschenfelde K Klin Wochenschr. 1981; 59(12):675-8.

PMID: 7253541 DOI: 10.1007/BF02593859.


Clinically important immunological processes in acute and fulminant hepatitis, mainly due to hepatitis B virus.

Mackenjee M, Kiepiela P, Cooper R, Coovadia H Arch Dis Child. 1982; 57(4):277-82.

PMID: 7082040 PMC: 1627636. DOI: 10.1136/adc.57.4.277.


The significance of the HBeAg/anti-HBe system in hemodialysis patients. A multicenter study.

Fiaccadori F, David S, Faggion G, Feriani N, Ferrari C, Franco V Infection. 1984; 12(1):23-6.

PMID: 6368400 DOI: 10.1007/BF01641020.


References
1.
Magnius L, Espmark A . A new antigen complex co-occurring with Australia antigen. Acta Pathol Microbiol Scand B Microbiol Immunol. 1972; 80(2):335-7. DOI: 10.1111/j.1699-0463.1972.tb00167.x. View

2.
ROBINSON W, Clayton D, Greenman R . DNA of a human hepatitis B virus candidate. J Virol. 1974; 14(2):384-91. PMC: 355524. DOI: 10.1128/JVI.14.2.384-391.1974. View

3.
El Sheikh N, Woolf I, Galbraith R, Eddleston A, Dymock I, Williams R . e Antigen-antibody system as indicator of liver damage in patients with hepatitis-B antigen. Br Med J. 1975; 4(5991):252-3. PMC: 1675054. DOI: 10.1136/bmj.4.5991.252. View

4.
Magnius L, ESPMARK J . New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol. 1972; 109(5):1017-21. View

5.
KAPLAN P, Gerin J, Alter H . Hepatitis B-specific DNA polymerase activity during post-transfusion hepatitis. Nature. 1974; 249(459):762-4. DOI: 10.1038/249762a0. View